Tag Archive for: lafora disease treatment

Open Letter to Noventia

Dear Noventia Pharma Team,

We are families affected by Lafora disease who are holding on to hope through your work. Your dedication to developing a treatment for Lafora means everything to us. We were excited when you shared the news of the ION283 license purchase and your intentions to create a clinical trial last year, but we are anxiously awaiting more details. We know that any future progress with ION283 will come from your company, so we kindly request a public update on what is next for the drug’s development after the safety study at UTSW.

As you know, the current ION283 safety study includes only 10 children. While we are grateful this study is happening, many more families were heartbroken to learn our children could not participate. These families are now left waiting, watching their children’s condition progress, and praying for the next opportunity. We are counting on Noventia to help make that opportunity possible.

For many of us, your work is the only hope we have left. Our children do not have time to wait. Lafora disease is aggressive and unforgiving—we are pleading for a chance to save our children’s lives. We desperately urge Noventia to share your plans and move forward quickly with a clinical trial or expanded access program so more children can receive this potentially life-saving treatment. You have our full support in this mission, and we are willing to assist however we can.

We would greatly appreciate it if you could share any updates with us or join our community for a Q&A. Some of our questions include:

  • How soon would expanded access be available for those not included in the trial?
  • What will be the initial phase of the clinical trial conducted by Noventia?
  • Which international sites will be involved?
  • Are those sites accredited to conduct a clinical trial?

We look forward to your prompt response and a clear outline of Noventia’s intentions regarding ION283. We are grateful for everything you do for the rare disease community and remain hopeful that Noventia will act swiftly to help more families in this fight against Lafora disease.

With hope,

The Lafora patient community

Patient organizations:

 
Asociacion CEL LUZ logo
Chelsea's Hope Lafora Children Research Fund

Lafora warriors and their families:

Hanifa Ishaque

Maggie Blatz

Anthony Caycho

Durmisevic Amar

Camila Bicca Oliveira

Caroline Bicca Oliveira

Prakash

Dr. Sagheer Hanif

Zarana Rathod

Tammie

Gonzalo Bruquetas

أم حسین الطباطبائي

Samy Sharif

Gladi Gidanian

Bilal Bhat

Bies Mahabier

Jamie Hennon

Marianne Rodriquez

Marina Weiss & Gajic Family

Georgianna

Spiros Georgakis

Paola Pacca

Romina Varesi

Silvana Parlato

Sami Memon

Marija Mrvosevic

Colleen Baumgartner-Hirsh

Simona Fochetti

Joan Monda

Babeth Letort

Jenifer Merriam

Recai yıldız

Marija Novakovic

Veronique Gadomski

Pierre Gadomski

Nuray yıldız

Fatos Malaj

Maha Hashim Alansari

Carmine Lettieri

Moniqueca Barfield

Jette Daubjerg

Elpida Georgaki

Nadira Belalouache

Fasal Alansari

Nora Belalouache

Hodosy Karol & Hodosy Viola Sheila Barter

Cheryl Bentley

Nicoletta Berti

Jette Daubjerg

Vanessa Lucas

Christophe Lucas

Kim Rice MD

Jim Rice MD

Tanja Weber

Antonello Giorgino

Daryoosh Moghaddam

Muhammad Malik

Mara Gerloni

Pasquale Esposito

Andi Müller

Anantha & Gopalakrishnan T

Korina Georgaki

 

Safety Study Update – February 2025

We are excited to share an update about the ION283 Safety Study: the team at UTSW can continue enrolling patients. 

In December 2024, the first patient in the Lafora Disease Safety Study at the University of Texas Southwestern Medical Center (USTW) received their first dose of ION283, a treatment designed to halt disease progression. Last month, that patient completed their one-month check-up with no safety issues detected. This allowed a second patient to receive their first dose of ION283 in January. Earlier in February, the second patient completed their one-month safety check. The safety board at the university reviewed the safety data, giving an all clear to proceed as planned with the study.

The first ten families who applied to participate in the study will receive notification from the team at UTSW when there is enough money available to enroll them in the study. We are pleased to share that the third patient is en route to Dallas, and the fourth has been notified.

As a community, we must continue raising funds so all 10 patients can receive treatment. The data collected from this study will help accelerate the approval process so that we can expand access for other patients to receive this drug. However, we need to complete the enrollment for this study first and get the data we need. So far, we have raised more than $977,000 as a community. We must reach 1.5 million dollars by May 2025 to fully fund the study. 

We will continue to keep the Lafora community informed about the progression of the Safety Study. Any questions not answered in our FAQs about the study can be directed to Chelsea’s Hope at info@chelseashope.org.

Lafora Disease Therapeutic Overview

We invite you to watch a video and read a page about the Lafora Disease Therapeutic Overview as of August 2023.

Are you wondering if there are future therapy options for Lafora Disease? Also, what treatments are in progress?

At last week’s event, Ask the Experts: A Q&A for Lafora Families, Chelsea’s Hope Science Director, Dr. Kit Donohue, shared an overview of treatment options in the pipeline. We are happy to share a short recording from the Q&A, as well as a PDF page with information from the presentation slideshow.

If you registered for the event, we’ve already sent you the full recording and handout. Make sure to check your email!

We hope the Q&A was informative and that participants could get their questions answered. Our team will work on creating handouts on Lafora Disease stages and on the importance of testing siblings of Lafora Disease patients. Please let us know if there are other resources we can provide to help you navigate living with Lafora.

Finally, Chelsea’s Hope is grateful for any volunteer who can translate materials from English to other languages. We encourage you to fill out the volunteer interest form if you can assist us.

Access the Lafora Disease Therapeutic Overview video captions in English HERE.

Access the transcript in Italian HERE.

Please email Dr. Donohue if you have any follow-up questions from the Q&A.